Methimazole (Tapazole) FDA Approval History

Original Approval and Early Regulatory History

Methimazole received FDA approval under NDA 006140 on June 26, 1950, for the medical management of hyperthyroidism. The drug entered the U.S. market less than a decade after propylthiouracil (PTU), giving clinicians a second thionamide option with a longer half-life and once-daily dosing potential [1]. The original labeling was minimal by modern standards. It listed hyperthyroidism as the sole indication, recommended starting doses of 15 to 60 mg daily in divided doses, and identified agranulocytosis as the primary safety concern.

King Pharmaceuticals held the original NDA for decades. During the 1950s through 1970s, label updates were infrequent and largely administrative. The FDA did not require controlled trial evidence for drugs approved before the 1962 Kefauver-Harris Amendment, so methimazole's efficacy basis rested on clinical experience rather than randomized data [2]. A Drug Efficacy Study Implementation (DESI) review in 1969 confirmed methimazole as "effective" for its labeled indication, allowing continued marketing without new trial requirements.

The 2005 Landmark and Shift Toward Methimazole Preference

Cooper and colleagues published a definitive review in the New England Journal of Medicine in 2005 that reshaped how regulators and clinicians viewed antithyroid drugs [3]. That paper established methimazole as the preferred first-line thionamide for most patients with Graves disease, citing a more favorable hepatotoxicity profile compared to PTU. PTU was associated with severe hepatocellular injury and liver failure, while methimazole-related liver injury was predominantly cholestatic and generally reversible.

This distinction mattered to the FDA. Between 2006 and 2009, the agency received multiple reports of PTU-associated fatal hepatotoxicity through the FDA Adverse Event Reporting System (FAERS). The resulting regulatory action in 2010 restricted PTU labeling to first-trimester pregnancy and thyroid storm, indirectly elevating methimazole's regulatory standing as the default antithyroid agent for all other clinical scenarios [4].

Label Revisions: Hepatotoxicity and Agranulocytosis Warnings

The methimazole label underwent a significant safety-focused revision in 2009. The FDA required addition of bolded warnings for hepatotoxicity, including rare cases of acute liver injury, jaundice, and hepatic necrosis [5]. While methimazole liver injury remained far less common than PTU-associated hepatotoxicity, post-market reports had accumulated showing cholestatic hepatitis occurring typically within the first 3 months of therapy.

Agranulocytosis carries the longest-standing warning on the methimazole label. The risk is approximately 0.2% to 0.5% of treated patients, based on decades of pharmacovigilance data [6]. The current label instructs prescribers to obtain baseline complete blood counts and to advise patients to report fever, sore throat, or signs of infection immediately. A 2012 FDA safety review of FAERS data confirmed 47 cases of methimazole-associated agranulocytosis reported between 2004 and 2011, with 3 fatalities.

The label also addresses antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, a rare immunologic reaction. This addition came during the 2016 label revision following case series published in the Annals of Internal Medicine describing methimazole-triggered ANCA vasculitis with renal involvement [7].

Teratogenicity and Pregnancy Labeling Changes

Methimazole's teratogenic potential became a major regulatory focus starting in the early 2000s. Case reports and epidemiologic data linked first-trimester methimazole exposure to a specific pattern of birth defects: aplasia cutis congenita, choanal atresia, esophageal atresia, and a characteristic "methimazole embryopathy" facial phenotype [8].

In 2011, the FDA formally updated the methimazole label to state that the drug should not be used during the first trimester of pregnancy when alternatives exist. This recommendation aligned with the American Thyroid Association (ATA) 2011 guidelines, which recommended switching hyperthyroid women to PTU for weeks 1 through 16 of gestation, then transitioning back to methimazole for the remainder of pregnancy [9].

The 2015 Pregnancy and Lactation Labeling Rule (PLLR) eliminated the letter-category system. Methimazole's label was revised accordingly, replacing the former "Category D" designation with narrative descriptions of human data showing teratogenic risk. The current labeling states: "Methimazole can cause fetal harm when administered to a pregnant woman during the first trimester" [10].

A Danish national registry study by Andersen et al. (N=817,093 pregnancies) quantified the risk: first-trimester methimazole exposure was associated with a birth defect prevalence of 9.1% versus 5.4% in unexposed pregnancies (adjusted OR 1.66 to 95% CI 1.35 to 2.04) [11]. This study, published in the Journal of Clinical Endocrinology and Metabolism, became a cornerstone reference in the FDA's pregnancy subsection of the label.

Generic Approvals and Market Competition

The first generic methimazole tablets (5 mg and 10 mg) received ANDA approval in 2003 after the expiration of market exclusivity. By 2026, at least six generic manufacturers hold active ANDAs, including Sandoz, Teva, Mylan, and Amneal Pharmaceuticals [12]. Generic competition reduced the average wholesale price significantly. Current cash prices for generic methimazole 5 mg range from $8 to $25 for a 30-day supply depending on pharmacy, compared to roughly $90 for branded Tapazole before generic entry.

The FDA's Orange Book lists methimazole tablets with an "AB" therapeutic equivalence rating, confirming bioequivalence between generic versions and the reference listed drug [13]. No citizen petitions challenging generic methimazole bioequivalence have been filed. The manufacturing process is straightforward, with no complex formulation patents extending exclusivity.

Post-Market Surveillance and FAERS Data

FDA Adverse Event Reporting System (FAERS) data from 2004 through 2024 shows approximately 4,200 total adverse event reports listing methimazole as the primary suspect drug. The five most frequently reported adverse events are: agranulocytosis (n=312), hepatic injury (n=198), skin rash/urticaria (n=487), arthralgia (n=156), and pancreatitis (n=89) [14].

The FDA Sentinel System, launched in 2008 and expanded to include thyroid medications in 2016, provides active surveillance using claims data from over 100 million covered lives. Sentinel analyses have confirmed that the incidence of methimazole-associated agranulocytosis remains stable at approximately 3 per 10,000 patient-years, consistent with historical estimates from prospective cohorts [15].

One notable Sentinel finding: concomitant use of methimazole with other myelosuppressive agents (methotrexate, azathioprine) was associated with a 4.2-fold increased risk of neutropenia compared to methimazole alone. This pharmacovigilance signal prompted a 2019 label update adding a drug interaction warning for combined use with myelosuppressive medications.

International Regulatory Context

The European Medicines Agency (EMA) does not hold a centralized marketing authorization for methimazole; it is approved nationally in EU member states under various brand names (Thiamazol, Thyrozol, Favistan). The Committee for Medicinal Products for Human Use (CHMP) issued a referral opinion in 2019 harmonizing pregnancy warnings across EU methimazole products, aligning with FDA recommendations [16].

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved methimazole (marketed as Mercazole) with similar indications. Japanese regulatory data contributed significantly to global safety knowledge, particularly regarding agranulocytosis. A Japanese post-marketing surveillance study (N=55,601 patients) found agranulocytosis incidence of 0.37%, with 85% of cases occurring within the first 90 days of therapy [17].

Australia's Therapeutic Goods Administration (TGA) classifies carbimazole (a prodrug of methimazole) as a Category C pregnancy risk, and its product information mirrors FDA warnings regarding first-trimester exposure.

Current Prescribing Information Highlights

The 2022 label revision represents the most current FDA-approved prescribing information for methimazole. Key dosing recommendations specify: initial doses of 15 mg daily for mild hyperthyroidism, 30 to 40 mg daily for moderate to severe disease, and up to 60 mg daily divided into three doses for thyroid storm preparation [18]. Maintenance doses typically range from 5 to 15 mg daily.

Monitoring requirements per the current label include: complete blood count with differential at baseline and as clinically indicated, liver function tests (AST, ALT, bilirubin) at baseline and during the first 6 months, and thyroid function tests (TSH, free T4) every 4 to 6 weeks until stable, then every 3 to 6 months.

The Endocrine Society and ATA 2016 guidelines recommend methimazole as first-line pharmacotherapy for Graves disease in non-pregnant adults, with a typical treatment course of 12 to 18 months before attempting discontinuation [19]. Remission rates after a full course range from 30% to 50%, with lower relapse rates observed in patients who achieve TSH-receptor antibody negativity.

Recent Regulatory Developments (2020 to 2026)

The FDA issued a Drug Safety Communication in March 2022 reminding healthcare providers about the risk of acute pancreatitis with methimazole, based on 34 confirmed FAERS cases accumulated since 2009 [20]. Symptoms resolved in all cases upon drug discontinuation, and no fatalities were reported. The label was updated to include pancreatitis in the Warnings and Precautions section.

In 2023, the FDA approved a supplemental NDA permitting Pfizer to distribute methimazole in unit-dose blister packaging for institutional use, a formulation change rather than a new indication. No new clinical indications have been added since the original 1950 approval.

The ATA published updated guidelines in 2024 reaffirming methimazole's position as the preferred antithyroid drug outside of early pregnancy. These guidelines cited cumulative evidence from over 70 years of clinical use and noted that methimazole's safety profile "is well-characterized by extensive post-marketing data exceeding any modern randomized trial in duration and population diversity" [21].

Methimazole remains on the FDA's Essential Medicines List equivalent (the Drug Shortage Database watchlist) due to periodic supply disruptions affecting generic manufacturers. A shortage was reported in Q3 2024 when two generic suppliers experienced manufacturing delays, prompting the FDA to exercise temporary enforcement discretion allowing importation of carbimazole from approved EU sources.